Buy Zytix (Abiraterone Acetate) 250 mg, Buy Zytiga 250 mg online.
Zytix / Zytiga (Abiraterone Acetate) 250 mg by Beacon Pharmaceuticals Bangladesh is a treatment for advanced prostate cancer.
Zytix is the alternative & generic version of Zytiga by Janssen Biotech, Inc. Zytix is manufactured by Beacon Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.
Abiraterone Acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with
-
Metastatic castration-resistant prostate cancer (CRPC).
-
Metastatic high-risk castration-sensitive prostate cancer (CSPC).
Therapeutic Class
Cytotoxic Chemotherapy
Pharmacology
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism. CYP17A1 is an enzyme that catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue.
More specifically, abiraterone inhibits the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 to decrease serum levels of testosterone and other androgens.
Dosage & Administration
Metastatic castration-resistant prostate cancer: Abiraterone 1,000 mg orally once daily with prednisone 5 mg orally twice daily.
Metastatic castration-sensitive prostate cancer: Abiraterone 1,000 mg orally once daily with prednisone 5 mg orally once daily.
Patients receiving Abiraterone / zytiga should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.
Dose Modification:
-
For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the Abiraterone starting dose to 250 mg once daily.
-
For patients who develop hepatotoxicity during treatment, hold Abiraterone until recovery. Retreatment may be initiated at a reduced dose. Abiraterone / zytiga should be discontinued if patients develop severe hepatotoxicity.